A colon cancer study

Using cancer cells in the blood to determine the type of chemotherapy that will benefit patients who have had surgery for colon cancer

CRC.10 | NCT 05174169

What is the purpose of this study?

The purpose of this study is to test if we can determine what kind of chemotherapy to offer patients based on whether or not circulating tumour DNA (ctDNA) is found in a blood test taken after surgery for colon cancer.

Why is this study important?

Using ctDNA testing to determine what kind of chemotherapy to use is a new approach. This approach seems promising, but it is not clear if it can offer better results than standard treatment.

Who can participate in this study?

This trial is for:

- Patients aged 18 or more
- Patients with confirmed Stage II or III colon cancer
- Patients with recent surgical treatment for colon cancer
- Patients who will be offered the standard post-surgery treatment options

This trial is not for:

- Patients with other cancer diagnoses within 5 years
- Patients with multiple primary colon cancers
- Patients with evidence of metastatic disease
- Patients who have had any previous treatment for colorectal cancer

CLINICAL TRIAL SPONSOR
Canadian Cancer Trials Group
Groupe canadien des essais sur le cancer

SHARE THIS SUMMARY WITH YOUR HEALTH CARE TEAM TO SEE IF THIS TRIAL IS A GOOD OPTION FOR YOU.

What are the risks?

If you choose to take part in this study, there is a risk that the new method of choosing your treatment may not be as good as the standard treatment. There is also a risk that you could have more side effects from more intensive chemotherapy treatment if that is recommended for you. Some of the most common side effects that the study doctors know about are: numbness/tingling, nausea, infection and hair loss. You will find details of all side effects in the consent document.

What can I expect?

If you choose to take part in this study, you will be entered into the trial and first have a blood test to see if you have ctDNA in your blood. If the test result is positive, you will then be randomly placed in one of two groups to receive either standard or intensified chemotherapy treatment. If the test result is negative, you will then be randomly placed in one of two other groups to receive either standard chemotherapy treatment or proceed with observation and monitoring only.

How can I find out more or join the study?

Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an *Informed Consent* document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The CRC.10 study is currently enrolling patients at cancer centres in Canada. For a full list of participating cancer centres please visit www.clinicaltrials.gov and search using NCT05174169. https://clinicaltrials.gov/ct2/show/NCT05174169

{for participating Centre's use - contact information, enrollment instructions, logo}